CAR-NK cells for B-cell autoimmune diseases
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 3 years old and have a diagnosis of lupus, nephrotic syndrome, or IgA nephropathy.
- Your disease must have been active despite trying at least two standard treatments for several months.
- You need to have adequate heart, kidney, liver, and lung function as measured by specific tests.
- You cannot have a recent serious infection, certain viral infections (like hepatitis or HIV), or other active major medical conditions.
- You must agree to use effective birth control for one year after the infusion if you are of childbearing age.
- You should not have received other B-cell-targeted treatments within the last month or participated in another clinical trial in the last three months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using special NK cells (a type of immune cell) designed to target and calm overactive B cells that cause autoimmune diseases like lupus and kidney inflammation. It may help children whose current treatments aren't working well enough.
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests a new type of immune cell therapy (CD19 CAR NK cells) for people with certain autoimmune diseases that have not responded to standard treatments. The goal is to see if these cells can safely reduce disease activity.
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.